Pediatric Systemic Lupus Erythematous in COVID-19 Era

• Published in: Viruses Vol. 15; no. 2; p. 272
• Main Authors: Lupu, Ancuta, Miron, Ingrith Crenguta, Gavrilovici, Cristina, Raileanu, Anca Adam, Starcea, Iuliana Magdalena, Ioniuc, Ileana, Azoicai, Alice, Mocanu, Adriana, Butnariu, Lacramioara Ionela, Dragan, Felicia, Lupu, Vasile Valeriu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.01.2023; MDPI
• Subjects: Adults; Antibodies; Asymptomatic; Autoimmune Diseases; Child; Children; Comorbidity; Coronaviruses; COVID-19; Demographic aspects; Development and progression; Diagnosis; Disease control; Diseases; Drugs; Epidemiology; Health aspects; Hospitalization; Humans; Immune system; Immunosuppression Therapy; Immunosuppressive agents; Infections; Lupus; Lupus Erythematosus, Systemic - complications; Medical research; Mortality; Pandemics; Pediatrics; Remission (Medicine); Review; Rheumatic diseases; Severe acute respiratory syndrome coronavirus 2; Systemic lupus erythematosus; vaccine; Viral infections; Romania; COVID-19; systemic lupus erythematosus; vaccine; child
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v15020272

Pediatric systemic lupus erythematosus is a chronic autoimmune disorder with a highly variable course and prognosis. It results in functional abnormalities in the immune system due to intrinsic factors and the use of immunosuppressive therapies associated with underlying comorbidities seem to increase the risk of severe COVID-19 and poor outcomes of the disease in pediatric systemic lupus erythematosus (SLE) patients. The aim of this review is to obtain a better understanding of the existing link between this new viral infection and pediatric lupus. We have analyzed the characteristics of newly diagnosed cases of pediatric SLE following COVID-19 which have been reported in the literature and which describe the impact that COVID-19 has on patients already suffering with pediatric SLE.